Ligand Pharmaceuticals, Inc. (LGND)
302.96
+0.22
(+0.07%)
USD |
NASDAQ |
Oct 02, 16:00
302.87
-0.09
(-0.03%)
After-Hours: 20:00
Ligand Pharmaceuticals Enterprise Value : 5.809B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 5.809B |
| October 01, 2026 | 5.804B |
| September 30, 2026 | 5.996B |
| September 29, 2026 | 5.956B |
| September 28, 2026 | 6.031B |
| September 25, 2026 | 5.780B |
| September 24, 2026 | 5.731B |
| September 23, 2026 | 5.718B |
| September 22, 2026 | 5.720B |
| September 21, 2026 | 5.552B |
| September 18, 2026 | 5.421B |
| September 17, 2026 | 5.445B |
| September 16, 2026 | 5.256B |
| September 15, 2026 | 5.291B |
| September 14, 2026 | 5.364B |
| September 11, 2026 | 5.440B |
| September 10, 2026 | 5.536B |
| September 09, 2026 | 5.512B |
| September 08, 2026 | 5.527B |
| September 04, 2026 | 5.463B |
| September 03, 2026 | 5.545B |
| September 02, 2026 | 5.489B |
| September 01, 2026 | 5.436B |
| August 31, 2026 | 5.433B |
| August 28, 2026 | 5.361B |
| Date | Value |
|---|---|
| August 27, 2026 | 5.441B |
| August 26, 2026 | 5.508B |
| August 25, 2026 | 5.386B |
| August 24, 2026 | 5.355B |
| August 21, 2026 | 5.477B |
| August 20, 2026 | 5.499B |
| August 19, 2026 | 5.565B |
| August 18, 2026 | 5.502B |
| August 17, 2026 | 5.586B |
| August 14, 2026 | 5.642B |
| August 13, 2026 | 5.527B |
| August 12, 2026 | 5.616B |
| August 11, 2026 | 5.526B |
| August 10, 2026 | 5.664B |
| August 07, 2026 | 5.613B |
| August 06, 2026 | 5.752B |
| August 05, 2026 | 5.801B |
| August 04, 2026 | 5.765B |
| August 03, 2026 | 5.591B |
| July 31, 2026 | 5.501B |
| July 30, 2026 | 5.676B |
| July 29, 2026 | 5.511B |
| July 28, 2026 | 5.676B |
| July 27, 2026 | 5.700B |
| July 24, 2026 | 5.760B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
| Zevra Therapeutics, Inc. | 372.75M |
| Liquidia Corp. | 2.451B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 48.51M |
| Revenue (Quarterly) | 63.69M |
| Total Expenses (Quarterly) | 15.18M |
| EPS Diluted (Quarterly) | 2.221 |
| Gross Profit Margin (Quarterly) | 82.24% |
| Profit Margin (Quarterly) | 76.16% |
| Earnings Yield | 3.09% |
| Operating Earnings Yield | 1.58% |
| Normalized Earnings Yield | 2.323 |